Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Oxford BioMedica on £25.7 Million Fundraising

July 10, 2014

LONDON, 2 June, 2014 — Oxford BioMedica plc, a Main Market listed gene based biopharmaceutical company, announced that it intends to raise gross proceeds of up to £25.7 million through a fundraising by means of a placing and subscriptions and an open offer. Covington & Burling advised the company on the transaction.

The proceeds of the fundraising will be used to continue to develop Oxford BioMedica’s business based on its LentiVector® platform, in particular to build on its growing ophthalmology portfolio.

John Dawson, Chief Executive Officer of Oxford BioMedica, commented: “This successful fundraise is a testament to our leading pipeline and development and manufacturing capabilities around our LentiVector® technology. There is now broad recognition of the growing trend within the gene and cell therapy sector and it is our focus to build Oxford BioMedica into a global leader in this field. The support of our existing and new shareholders in this fundraising brings us the financial stability to now drive significant value for the future.”

The Covington team was led by partner Natalie Walter, and included associates Sarah Hoult and Kate Badr. Partner Kristian Wiggert advised on US aspects of the transaction.

Share this article: